Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/13256
A 9-VALENT HPV VACCINE AGAINST INFECTION AND INTRAEPITHELIAL NEOPLASIA IN WOMEN
Neoplasia Intraepitelial Cervical/prevenção & controle
Infecções por Papillomavirus/prevenção & controle
Vacinas contra Papillomavirus
Neoplasias do Colo do Útero/prevenção & controle
Adolescente
Adulto
Anticorpos Antivirais/sangue
Neoplasia Intraepitelial Cervical/virologia
Método Duplo-Cego
Feminino
Doenças dos Genitais Femininos/epidemiologia
Humanos
Incidência
Análise de Intenção de Tratamento
Infecções por Papillomavirus/epidemiologia
Vacinas contra Papillomavirus/administração & dosagem
Neoplasias do Colo do Útero/virologia
Autor(es)
Joura, E. A.
Giuliano, Anna R.
Iversen, O. E.
Bouchard, C.
Mao, C.
Mehlsen, J.
Moreira Júnior, Edson Duarte
Ngan, Y.
Petersen, L. K.
Lazcano‑Ponce, E.
Pitisuttithum, P.
Restrepo, J. A.
Stuart, G.
Woelber, L.
Yang, Y. C.
Cuzick, J.
Garland, S. M.
Huh, W.
Kjaer, S. K.
Bautista, Oliver M.
Chan, I. S. F.
Chen, J.
Gesser, R.
Moeller, E.
Ritter, M.
Vuocolo, S.
Luxembourg, A.
Broad Spectrum HPV Vaccine Study
Giuliano, Anna R.
Iversen, O. E.
Bouchard, C.
Mao, C.
Mehlsen, J.
Moreira Júnior, Edson Duarte
Ngan, Y.
Petersen, L. K.
Lazcano‑Ponce, E.
Pitisuttithum, P.
Restrepo, J. A.
Stuart, G.
Woelber, L.
Yang, Y. C.
Cuzick, J.
Garland, S. M.
Huh, W.
Kjaer, S. K.
Bautista, Oliver M.
Chan, I. S. F.
Chen, J.
Gesser, R.
Moeller, E.
Ritter, M.
Vuocolo, S.
Luxembourg, A.
Broad Spectrum HPV Vaccine Study
Afiliação
The Medical University of Vienna. Comprehensive Cancer Center. Vienna.
Moffitt Cancer Center. Tampa, Florida, USA.
University of Bergen–Haukeland University Hospital. Department of Clinical Medicine. Bergen, Norway.
Université Laval. Québec, Canadá.
University of Washington. Seattle, USA.
University of Copenhagen. Coordinating Research Center. Frederiksberg Hospital. Copenhagen.
Associação Obras Sociais Irmã Dulce. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil.
University of Hong Kong. Hong Kong.
Aarhus University Hospital. Department of Obstetrics and Gynecology. Aarhus, Denmark.
Instituto Nacional de Salud Pública. Cuernavaca, Morelos, Mexico.
Mahidol University. Faculty of Tropical Medicine. Nakhon Pathom, Thailand.
Investigación Clínica. Medellín, Colombia.
University of British Columbia. Vancouver, Canada.
University Medical Center Hamburg–Eppendorf. Department of Gynecology. Hamburg, Germany.
Mackay Memorial Hospital. Taipei, Taiwan.
Wolfson Institute of Preventive Medicine. London.
Royal Women’s Hospital. University of Melbourne and Murdoch Childrens Research Institute. Parkville, VIC, Australia.
University of Alabama. Division of Gynecologic Oncology. Birmingham.
Danish Cancer Society Research Center and Department of Gynecology. Rigshospitalet, Copenhagen.
University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.
University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.
University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.
University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.
University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.
University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.
University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ
University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.
Broad Spectrum HPV Vaccine Study.
Moffitt Cancer Center. Tampa, Florida, USA.
University of Bergen–Haukeland University Hospital. Department of Clinical Medicine. Bergen, Norway.
Université Laval. Québec, Canadá.
University of Washington. Seattle, USA.
University of Copenhagen. Coordinating Research Center. Frederiksberg Hospital. Copenhagen.
Associação Obras Sociais Irmã Dulce. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil.
University of Hong Kong. Hong Kong.
Aarhus University Hospital. Department of Obstetrics and Gynecology. Aarhus, Denmark.
Instituto Nacional de Salud Pública. Cuernavaca, Morelos, Mexico.
Mahidol University. Faculty of Tropical Medicine. Nakhon Pathom, Thailand.
Investigación Clínica. Medellín, Colombia.
University of British Columbia. Vancouver, Canada.
University Medical Center Hamburg–Eppendorf. Department of Gynecology. Hamburg, Germany.
Mackay Memorial Hospital. Taipei, Taiwan.
Wolfson Institute of Preventive Medicine. London.
Royal Women’s Hospital. University of Melbourne and Murdoch Childrens Research Institute. Parkville, VIC, Australia.
University of Alabama. Division of Gynecologic Oncology. Birmingham.
Danish Cancer Society Research Center and Department of Gynecology. Rigshospitalet, Copenhagen.
University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.
University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.
University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.
University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.
University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.
University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.
University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ
University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.
Broad Spectrum HPV Vaccine Study.
Resumo em Inglês
BACKGROUND: The investigational 9-valent viruslike particle vaccine against human papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6, 11, 16, and 18) and five additional oncogenic types (31, 33, 45, 52, and 58). Here we present the results of a study of the efficacy and immunogenicity of the 9vHPV vaccine in women 16 to 26 years of age. METHODS: We performed a randomized, international, double-blind, phase 2b-3 study of the 9vHPV vaccine in 14,215 women. Participants received the 9vHPV vaccine or the qHPV vaccine in a series of three intramuscular injections on day 1 and at months 2 and 6. Serum was collected for analysis of antibody responses. Swabs of labial, vulvar, perineal, perianal, endocervical, and ectocervical tissue were obtained and used for HPV DNA testing, and liquid-based cytologic testing (Papanicolaou testing) was performed regularly. Tissue obtained by means of biopsy or as part of definitive therapy (including a loop electrosurgical excision procedure and conization) was tested for HPV. RESULTS: The rate of high-grade cervical, vulvar, or vaginal disease irrespective of HPV type (i.e., disease caused by HPV types included in the 9vHPV vaccine and those not included) in the modified intention-to-treat population (which included participants with and those without prevalent infection or disease) was 14.0 per 1000 person-years in both vaccine groups. The rate of high-grade cervical, vulvar, or vaginal disease related to HPV-31, 33, 45, 52, and 58 in a prespecified per-protocol efficacy population (susceptible population) was 0.1 per 1000 person-years in the 9vHPV group and 1.6 per 1000 person-years in the qHPV group (efficacy of the 9vHPV vaccine, 96.7%; 95% confidence interval, 80.9 to 99.8). Antibody responses to HPV-6, 11, 16, and 18 were noninferior to those generated by the qHPV vaccine. Adverse events related to injection site were more common in the 9vHPV group than in the qHPV group. CONCLUSIONS: The 9vHPV vaccine prevented infection and disease related to HPV-31, 33, 45, 52, and 58 in a susceptible population and generated an antibody response to HPV-6, 11, 16, and 18 that was noninferior to that generated by the qHPV vaccine. The 9vHPV vaccine did not prevent infection and disease related to HPV types beyond the nine types covered by the vaccine.
DeCS
AlphapapillomavirusNeoplasia Intraepitelial Cervical/prevenção & controle
Infecções por Papillomavirus/prevenção & controle
Vacinas contra Papillomavirus
Neoplasias do Colo do Útero/prevenção & controle
Adolescente
Adulto
Anticorpos Antivirais/sangue
Neoplasia Intraepitelial Cervical/virologia
Método Duplo-Cego
Feminino
Doenças dos Genitais Femininos/epidemiologia
Humanos
Incidência
Análise de Intenção de Tratamento
Infecções por Papillomavirus/epidemiologia
Vacinas contra Papillomavirus/administração & dosagem
Neoplasias do Colo do Útero/virologia
Compartilhar